AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 11708572 — intervention group
Group type: EXPERIMENTAL
Intervention: paracetamol 500 mg plus hyoscine N‐butylbromide 10 mg
Number of subjects: 125
Study 11708572 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 125
Study 11708572 — intervention group
Group type: COMPARATOR
Intervention: baseline
Number of subjects: 125
Study 9190553 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (INO) at 20 ppm
Number of subjects: 53
Study 9190553 — intervention group
Group type: COMPARATOR
Intervention: Control (100% oxygen)
Number of subjects: 53
Study 1405330 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 121
Study 1405330 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine
Number of subjects: 121
Study 3874774 — intervention group
Group type: EXPERIMENTAL
Intervention: Phentolamine (25 micrograms kg‐1 min‐1)
Number of subjects: 20
Study 3874774 — intervention group
Group type: EXPERIMENTAL
Intervention: Urapidil (100 micrograms kg‐1 min‐1)
Number of subjects: 20
Study 30689172 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Reality training (VR group)
Number of subjects: 10
Study 30689172 — intervention group
Group type: COMPARATOR
Intervention: Control group (without VR training)
Number of subjects: 10
Study 28650790 — intervention group
Group type: EXPERIMENTAL
Intervention: Demonstration on a Model by Tell and Touch method (DMTT)
Number of subjects: 60
Study 28650790 — intervention group
Group type: COMPARATOR
Intervention: Lecture
Number of subjects: 60
Study 28650790 — intervention group
Group type: COMPARATOR
Intervention: Self trained on oral hygiene skills
Number of subjects: 60
Study 26535595 — intervention group
Group type: EXPERIMENTAL
Intervention: DR-prednisone
Number of subjects: 207
Study 26535595 — intervention group
Group type: COMPARATOR
Intervention: IR-prednisone
Number of subjects: 207
Study 23932307 — intervention group
Group type: EXPERIMENTAL
Intervention: IUI at 34‐36 h after hCG injection (group I, n=106)
Number of subjects: 220
Study 23932307 — intervention group
Group type: EXPERIMENTAL
Intervention: IUI simultaneously with hCG administration (group II, n=98)
Number of subjects: 220
Study 20736941 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc salt (ZnCl2)
Number of subjects: 12
Study 20736941 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic low-dose zinc exposure
Number of subjects: 12
Study 20736941 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of ZnCl2
Number of subjects: 12
Study 20736941 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 20736941 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc salt and proton pump inhibitor (PPI)
Number of subjects: 12
Study 19750306 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural analgesia with 15 mL of 0.125% ropivacaine (EA group)
Number of subjects: 40
Study 19750306 — intervention group
Group type: COMPARATOR
Intervention: Combined spinal-epidural (CSE group) with 5 microg of sufentanil plus 2.5mg bupivacaine
Number of subjects: 40
Study 19750306 — intervention group
Group type: COMPARATOR
Intervention: Combined spinal-epidural (CSE group)
Number of subjects: 40
Study 17406133 — intervention group
Group type: EXPERIMENTAL
Intervention: Adult male circumcision
Number of subjects: 1475
Study 12848630 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice-daily: lansoprazole 30 mg, clarithromycin 250 mg and tinidazole 500 mg
Number of subjects: 296
Study 12848630 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-daily: lansoprazole 60 mg, clarithromycin 500 mg and tinidazole 1000 mg
Number of subjects: 296
Study 12848630 — intervention group
Group type: COMPARATOR
Intervention: Once-daily: placebo, clarithromycin 500 mg and tinidazole 1000 mg
Number of subjects: 296
Study 10671705 — intervention group
Group type: EXPERIMENTAL
Intervention: Remedial intervention (four 45-minute sessions of participation in computer tasks without instruction in compensatory strategies)
Number of subjects: 30
Study 10671705 — intervention group
Group type: EXPERIMENTAL
Intervention: Compensatory intervention (four 45-minute sessions of instruction in the use of three internal compensatory strategies: verbalization, chunking, and pacing)
Number of subjects: 30
Study 10671705 — intervention group
Group type: COMPARATOR
Intervention: Both groups (remedial and compensatory)
Number of subjects: 30
Study 8923366 — intervention group
Group type: EXPERIMENTAL
Intervention: Beraprost sodium (oral prostanoid prostaglandin I2 analog)
Number of subjects: 125
Study 8923366 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 125
Study 8923366 — intervention group
Group type: EXPERIMENTAL
Intervention: Beraprost sodium
Number of subjects: 125
Study 8923366 — intervention group
Group type: EXPERIMENTAL
Intervention: Beraprost sodium and Placebo
Number of subjects: 125
Study 1756692 — intervention group
Group type: EXPERIMENTAL
Intervention: Amidotrizoic acid (2.1 osmol/kg; mean dosage 166 +/- 68 or 2.2 +/- 1.1 ml/kg)
Number of subjects: 30
Study 1756692 — intervention group
Group type: COMPARATOR
Intervention: Iopamidol (0.8 osmol/kg; mean dosage 154 +/- 78 ml or 2.1 +/- 1.0 ml/kg)
Number of subjects: 30
Study 7124768 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 6200729 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (0.0125 to 0.15 mg/kg)
Number of subjects: 16
Study 6200729 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 29458320 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mL/min
Number of subjects: 100
Study 29458320 — intervention group
Group type: COMPARATOR
Intervention: 250 mL/min
Number of subjects: 100
Study 27158033 — intervention group
Group type: EXPERIMENTAL
Intervention: Acrylic resin-based surgical guides (Sg)
Number of subjects: 40
Study 27158033 — intervention group
Group type: COMPARATOR
Intervention: Conventional surgery (Co)
Number of subjects: 40
Study 25436797 — intervention group
Group type: EXPERIMENTAL
Intervention: Crizotinib
Number of subjects: 343
Study 25436797 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy (Pemetrexed)
Number of subjects: 343
Study 25436797 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy (Docetaxel)
Number of subjects: 343
Study 22089480 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal BMI athletes (n = 150)
Number of subjects: 938
Study 22089480 — intervention group
Group type: COMPARATOR
Intervention: Normal BMI controls (n = 96)
Number of subjects: 938
Study 22089480 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between BMI and body fat percentage for athletes
Number of subjects: 938
Study 22089480 — intervention group
Group type: COMPARATOR
Intervention: Correlation between BMI and body fat percentage for controls
Number of subjects: 938
Study 19696755 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week aerobic exercise program (4 x 30 min/week at >=70% of peak oxygen consumption (VO2peak))
Number of subjects: 29
Study 17327869 — intervention group
Group type: EXPERIMENTAL
Intervention: Boiled potatoes (energy-equivalent meal)
Number of subjects: 27
Study 17327869 — intervention group
Group type: EXPERIMENTAL
Intervention: French fries (energy-equivalent meal)
Number of subjects: 27
Study 17327869 — intervention group
Group type: EXPERIMENTAL
Intervention: Boiled potatoes (carbohydrate-equivalent meal)
Number of subjects: 27
Study 17327869 — intervention group
Group type: EXPERIMENTAL
Intervention: French fries (carbohydrate-equivalent meal)
Number of subjects: 27
Study 17327869 — intervention group
Group type: EXPERIMENTAL
Intervention: Boiled potatoes with oil (carbohydrate-equivalent meal)
Number of subjects: 27
Study 17327869 — intervention group
Group type: COMPARATOR
Intervention: White wheat bread (reference meal)
Number of subjects: 27
Study 15977092 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral rofecoxib 50 mg 1 h before surgery plus intraarticular 0.5 % bupivacaine 20 ml postoperatively
Number of subjects: 62
Study 15977092 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraarticular 0.5 % bupivacaine 20 ml postoperatively
Number of subjects: 62
Study 15977092 — intervention group
Group type: COMPARATOR
Intervention: Saline 20 ml intraarticularly after surgery
Number of subjects: 62
Study 12681866 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous use of 20 microg ethinyl estradiol/100 microg levonorgestrel for 12 cycles (336 days)
Number of subjects: 79
Study 12681866 — intervention group
Group type: COMPARATOR
Intervention: 28-day cycles (21 active pills and a pill-free week)
Number of subjects: 79
Study 12681866 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous use of 20 microg ethinyl estradiol/100 microg levonorgestrel
Number of subjects: 79
Study 10640841 — intervention group
Group type: EXPERIMENTAL
Intervention: Eosin 2% solution
Number of subjects: 54
Study 10640841 — intervention group
Group type: COMPARATOR
Intervention: Zinc oxide paste
Number of subjects: 54
Study 10640841 — intervention group
Group type: COMPARATOR
Intervention: Corticosteroid cream (clobetasone butyrate 0.05%)
Number of subjects: 54
Study 9038393 — intervention group
Group type: EXPERIMENTAL
Intervention: Histopathologic examination of endometrial hyperplasias
Number of subjects: 87
Study 1542817 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadriceps endurance programme (experimental group)
Number of subjects: 22
Study 1542817 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 22
Study 6601201 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive medical management
Number of subjects: 70
Study 6601201 — intervention group
Group type: COMPARATOR
Intervention: Urgent coronary bypass surgery
Number of subjects: 70
Study 6601201 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary bypass surgery
Number of subjects: 70
Study 30315239 — intervention group
Group type: EXPERIMENTAL
Intervention: ibrutinib (420 mg daily) + bendamustine and rituximab (BR)
Number of subjects: 578
Study 30315239 — intervention group
Group type: COMPARATOR
Intervention: placebo + bendamustine and rituximab (BR)
Number of subjects: 578
Study 30315239 — intervention group
Group type: EXPERIMENTAL
Intervention: ibrutinib + BR
Number of subjects: 578
Study 30315239 — intervention group
Group type: COMPARATOR
Intervention: placebo + BR
Number of subjects: 578
Study 28988209 — intervention group
Group type: EXPERIMENTAL
Intervention: Forced air warming (FAW)
Number of subjects: 140
Study 28988209 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 140
Study 26073718 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-based educational program (CHOICES)
Number of subjects: 68
Study 26073718 — intervention group
Group type: COMPARATOR
Intervention: Usual care reformatted into a computer-based (e-Book) program
Number of subjects: 68
Study 24854049 — intervention group
Group type: EXPERIMENTAL
Intervention: Inpatient weight loss intervention with postdischarge follow-up (weight education video, personalized counseling, specific goals)
Number of subjects: 176
Study 24854049 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 176
Study 24854049 — intervention group
Group type: EXPERIMENTAL
Intervention: Inpatient weight loss intervention with postdischarge follow-up
Number of subjects: 176
Study 24854049 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 176
Study 22401952 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketofol
Number of subjects: 284
Study 22401952 — intervention group
Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 284
Study 19565176 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening for osteoporosis
Number of subjects: 4800
Study 19565176 — intervention group
Group type: COMPARATOR
Intervention: No screening (control)
Number of subjects: 4800
Study 18611422 — intervention group
Group type: EXPERIMENTAL
Intervention: Live attenuated influenza vaccine (LAIV)
Number of subjects: 0
Study 18611422 — intervention group
Group type: COMPARATOR
Intervention: Trivalent inactivated influenza vaccine (TIV)
Number of subjects: 0
Study 16202724 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic approach
Number of subjects: 84
Study 16202724 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparotomic approach
Number of subjects: 84
Study 16202724 — intervention group
Group type: COMPARATOR
Intervention: Control group (matched women)
Number of subjects: 84
Study 10921154 — intervention group
Group type: EXPERIMENTAL
Intervention: Huweigao externally applied at Shenque (Ren 8)
Number of subjects: 140
Study 10921154 — intervention group
Group type: COMPARATOR
Intervention: Weinaian capsule (oral administration)
Number of subjects: 140
Study 8520750 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% nedocromil sodium
Number of subjects: 93
Study 8520750 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 93
Study 1664792 — intervention group
Group type: EXPERIMENTAL
Intervention: Diets containing different amounts of protein and phosphorus with two levels of blood pressure control.
Number of subjects: 0
Study 1664792 — intervention group
Group type: COMPARATOR
Intervention: Blood pressure control levels.
Number of subjects: 0
Study 7038656 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-daily metoprolol
Number of subjects: 0
Study 7038656 — intervention group
Group type: COMPARATOR
Intervention: Twice-daily metoprolol
Number of subjects: 0
Study 27837321 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemiarthroplasty (HA)
Number of subjects: 78
Study 27837321 — intervention group
Group type: COMPARATOR
Intervention: Internal Fixation (IF)
Number of subjects: 78
Study 24903408 — intervention group
Group type: EXPERIMENTAL
Intervention: Less sweet beverages available at home
Number of subjects: 2047
Study 24903408 — intervention group
Group type: EXPERIMENTAL
Intervention: Parents discouraged sweet beverage consumption
Number of subjects: 2047
Study 23952184 — intervention group
Group type: EXPERIMENTAL
Intervention: Children with ADHD and one comorbid condition (ODD or ADs)
Number of subjects: 223
Study 23952184 — intervention group
Group type: EXPERIMENTAL
Intervention: Children with ADHD and two comorbid conditions (ODD and ADs)
Number of subjects: 223
Study 23952184 — intervention group
Group type: COMPARATOR
Intervention: Children with ADHD alone
Number of subjects: 223
Study 20716629 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-treatment Ki-67 in the second quartile (14%-19%)
Number of subjects: 120
Study 20716629 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-treatment Ki-67 in the third quartile (20%-29%)
Number of subjects: 120
Study 20716629 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-treatment Ki-67 in the top quartile (≥30%)
Number of subjects: 120
Study 20716629 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline Ki-67
Number of subjects: 120
Study 19761888 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week worksite health promotion program in obese group with Apo E3 genotype
Number of subjects: 141
Study 19761888 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week worksite health promotion program in individuals with Apo E2 genotype
Number of subjects: 141
Study 19761888 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week worksite health promotion program in individuals with Apo E3 genotype
Number of subjects: 141
Study 19761888 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week worksite health promotion program in individuals with Apo E4 genotype
Number of subjects: 141
Study 16938752 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerosolized rhDNase (Pulmozyme) 2(1/2) mg once daily
Number of subjects: 0
Study 16938752 — intervention group
Group type: COMPARATOR
Intervention: No rhDNase treatment (control group)
Number of subjects: 0
Study 15361814 — intervention group
Group type: EXPERIMENTAL
Intervention: Subclinical hypothyroidism (SH)
Number of subjects: 44
Study 15361814 — intervention group
Group type: COMPARATOR
Intervention: Overt hypothyroidism (OH)
Number of subjects: 44
Study 15361814 — intervention group
Group type: COMPARATOR
Intervention: Euthyroid controls
Number of subjects: 44
Study 11028260 — intervention group
Group type: EXPERIMENTAL
Intervention: Atracurium (A)
Number of subjects: 151
Study 11028260 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisatracurium (C)
Number of subjects: 151
Study 11028260 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium (R)
Number of subjects: 151
Study 9550765 — intervention group
Group type: EXPERIMENTAL
Intervention: Mini-Mental State Examination (MMSE)
Number of subjects: 2151
Study 8382419 — intervention group
Group type: EXPERIMENTAL
Intervention: Live oral candidate rotavirus vaccines (RIT 4237, RRV‐1, DxRRV, DS1xRRV)
Number of subjects: 0
Study 3764377 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporin A
Number of subjects: 0
Study 3764377 — intervention group
Group type: COMPARATOR
Intervention: Prednisone
Number of subjects: 0
Study 30353020 — intervention group
Group type: EXPERIMENTAL
Intervention: ADDWoR group
Number of subjects: 32
Study 30353020 — intervention group
Group type: EXPERIMENTAL
Intervention: OVX+ ADDWoR group
Number of subjects: 32
Study 30353020 — intervention group
Group type: COMPARATOR
Intervention: OVX group
Number of subjects: 32
Study 30353020 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 32
Study 27297006 — intervention group
Group type: EXPERIMENTAL
Intervention: Newhints intervention with CBSV assessments and referrals
Number of subjects: 16168
Study 27297006 — intervention group
Group type: COMPARATOR
Intervention: Control group (no Newhints intervention)
Number of subjects: 16168
Study 25533656 — intervention group
Group type: EXPERIMENTAL
Intervention: Latanoprost 0.005% eye drops, administered once a day to both eyes.
Number of subjects: 516
Study 25533656 — intervention group
Group type: COMPARATOR
Intervention: Placebo eye drops, administered once a day to both eyes.
Number of subjects: 516
Study 25533656 — intervention group
Group type: EXPERIMENTAL
Intervention: Latanoprost 0.005% eye drops
Number of subjects: 516
Study 25533656 — intervention group
Group type: COMPARATOR
Intervention: Placebo eye drops
Number of subjects: 516
Study 23910248 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone outreach intervention
Number of subjects: 50
Study 23910248 — intervention group
Group type: COMPARATOR
Intervention: Cancer helpline calls
Number of subjects: 50
Study 21788846 — intervention group
Group type: EXPERIMENTAL
Intervention: Transversus abdominis plane block
Number of subjects: 28
Study 19431219 — intervention group
Group type: EXPERIMENTAL
Intervention: Pneumatic dilatation (n = 26)
Number of subjects: 51
Study 19431219 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic myotomy (n = 25)
Number of subjects: 51
Study 19431219 — intervention group
Group type: EXPERIMENTAL
Intervention: TBE parameter (height of barium column at 1 min)
Number of subjects: 51
Study 19431219 — intervention group
Group type: EXPERIMENTAL
Intervention: TBE parameter (height at 1 min) post-treatment
Number of subjects: 51
Study 16702582 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice-a-week weight training for 6 months
Number of subjects: 45
Study 15526714 — intervention group
Group type: EXPERIMENTAL
Intervention: Congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency
Number of subjects: 0
Study 15526714 — intervention group
Group type: EXPERIMENTAL
Intervention: Salt-losing CAH
Number of subjects: 0
Study 15526714 — intervention group
Group type: COMPARATOR
Intervention: Control group (sisters of CAH participants and women with polycystic ovary syndrome)
Number of subjects: 0
Study 11391583 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel 40 mg/m2 and estramustine 600 mg/m2 (Cohort I)
Number of subjects: 18
Study 11391583 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel 60 mg/m2 and estramustine 900 mg/m2 (Cohort II)
Number of subjects: 18
Study 11391583 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel 75 mg/m2 and estramustine 900 mg/m2 (Cohort III)
Number of subjects: 18
Study 11391583 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel 90 mg/m2 and estramustine 900 mg/m2 (Cohort IV)
Number of subjects: 18
Study 11391583 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall response in Cohorts I-IV
Number of subjects: 18
Study 11391583 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall response in Cohorts II-IV
Number of subjects: 18
Study 11391583 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall response with measurable disease
Number of subjects: 18
Study 11391583 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall PSA response
Number of subjects: 18
Study 11391583 — intervention group
Group type: EXPERIMENTAL
Intervention: Median duration of PSA response
Number of subjects: 18
Study 9493121 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil 4-16 mg once a day
Number of subjects: 5000
Study 9493121 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil 8 mg
Number of subjects: 5000
Study 9493121 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil in combination with amlodipine or hydrochlorothiazide
Number of subjects: 5000
Study 9493121 — intervention group
Group type: COMPARATOR
Intervention: Candesartan cilexetil
Number of subjects: 5000
Study 7648152 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete local clearance as assessed by surgeon and pathologist
Number of subjects: 396
Study 7648152 — intervention group
Group type: COMPARATOR
Intervention: Incomplete local clearance as assessed by surgeon and pathologist
Number of subjects: 396
Study 7648152 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete local clearance in patients without metastatic disease
Number of subjects: 396
Study 7648152 — intervention group
Group type: COMPARATOR
Intervention: Incomplete local clearance in patients without metastatic disease
Number of subjects: 396
Study 7648152 — intervention group
Group type: COMPARATOR
Intervention: Disagreement in assessment of local clearance
Number of subjects: 396
Study 2669713 — intervention group
Group type: EXPERIMENTAL
Intervention: Papaverine (60 mg)
Number of subjects: 34
Study 2669713 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenoxybenzamine (6 mg)
Number of subjects: 34
Study 2669713 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (10 ml)
Number of subjects: 34
Study 1001084 — intervention group
Group type: EXPERIMENTAL
Intervention: Ammonium hydroxide odor source presented near the nose
Number of subjects: 20
Study 31513839 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 g E. angustifolia whole fruit powder
Number of subjects: 58
Study 31513839 — intervention group
Group type: COMPARATOR
Intervention: Placebo (7.5 g cornstarch + 7.5 g isomalt)
Number of subjects: 58